@article {1328875,
	title = {Early Response to Anti-Vascular Endothelial Growth Factor and Two-Year Outcomes Among Eyes With Diabetic Macular Edema in Protocol T},
	journal = {Am J Ophthalmol},
	volume = {195},
	year = {2018},
	month = {2018 Nov},
	pages = {93-100},
	abstract = {PURPOSE: Assess associations of 2-year visual acuity (VA) outcomes with VA and optical coherence tomography central subfield thickness (CST) after 12\&nbsp;weeks of anti-vascular endothelial growth factor treatment for diabetic macular edema in DRCR.net Protocol T. DESIGN: Randomized clinical trial. METHODS: Setting: Multicenter (89\&nbsp;U.S. sites). PATIENT POPULATION: Eyes with VA and CST data from baseline and 12-week visits (616 of 660 eyes randomized [93.3\%]). INTERVENTION: Six monthly injections of 2.0\&nbsp;mg aflibercept, 1.25\&nbsp;mg bevacizumab, or 0.3\&nbsp;mg ranibizumab; subsequent injections and focal/grid laser as needed for stability. MAIN OUTCOME MEASURES: Change in VA from baseline and VA letter score at 2 years. RESULTS: Twelve-week VA response was associated with 2-year change in VA and 2-year VA letter score for each drug (P \&lt; .001) but with substantial individual variability (multivariable R\&nbsp;= 0.38, 0.29, and 0.26 for 2-year change with aflibercept, bevacizumab, and ranibizumab, respectively). Among eyes with less than 5-letter gain at 12\&nbsp;weeks, the percentages of eyes gaining 10 or more letters from baseline at 2 years were 42\% (20 of 48), 31\% (21 of 68), and 47\% (28 of 59), and median 2-year VA was 20/32, 20/32, and 20/25, in the aflibercept, bevacizumab, and ranibizumab groups, respectively. Twelve-week CST response was not strongly associated with 2-year outcomes. CONCLUSIONS: A suboptimal response at 12\&nbsp;weeks did not preclude meaningful vision improvement (ie, >= 10-letter gain) in many eyes at 2 years. Eyes with less than 5-letter gain at 12\&nbsp;weeks often had good VA at 2 years without switching therapies.},
	issn = {1879-1891},
	doi = {10.1016/j.ajo.2018.07.030},
	author = {Bressler, Neil M and Beaulieu, Wesley T and Maguire, Maureen G and Glassman, Adam R and Blinder, Kevin J and Bressler, Susan B and Gonzalez, Victor H and Jampol, Lee M and Melia, Michele and Sun, Jennifer K and Wells, John A and Diabetic Retinopathy Clinical Research Network}
}
